SAN MATEO, Calif., September 09, 2024--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25.
"We are excited to welcome Matt, who brings a wealth of global pharmaceutical experience, including leading the commercialization of blockbuster franchises at multiple multinational companies," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "Matt’s management will be pivotal as we continue our leadership in hematology with BRUKINSA and replicate that success in solid tumors, with a deep and exciting pipeline of innovative therapies."
Mr. Shaulis is a global commercial executive with over 20 years of experience at biopharmaceutical companies such as Hansa Biopharma, Pfizer, Teva, Cephalon, and Johnson & Johnson. While at Pfizer, he directed the U.S. commercialization of blockbuster therapies IBRANCE? and XTANDI? as well as leading Pfizer’s acquisition and integration of Medivation.
Mr. Shaulis, who has prior experience commercializing therapies for chronic lymphocytic leukemia (CLL), will direct the commercialization of BTK inhibitor BRUKINSA? (zanubrutinib) as well as anti-PD-1 antibody TEVIMBRA? (tislelizumab) in North America, spearhead the launch of future assets in hematology and solid tumors, and lead the cross-functional North America Leadership Team in this important region.
"I am honored to join BeiGene at a transformative moment for the Company and drive the commercial growth of impactful medicines BRUKINSA and TEVIMBRA in North America," said Mr. Shaulis. "As BeiGene continues to advance its growing pipeline of therapies, I am eager to lead this exceptional team to new milestones and extend our reach to more patients in this important region."
Josh Neiman, Chief Commercial Officer, North America & Europe, will leave the Company to pursue a new entrepreneurial opportunity at a healthcare technology startup.
"I want to extend my gratitude to Josh for his leadership and invaluable contributions in building BeiGene’s commercial organization in the U.S. and Europe. His commitment and vision shaped our success," Mr. Oyler added. "Josh played a crucial role in propelling BRUKINSA to global blockbuster status through outstanding launches in the U.S. and Europe, and in establishing robust commercial capabilities in these key regions for our solid tumor portfolio. The exceptional commercial leadership team he helped assemble will be instrumental in sustaining our success and driving future growth under Matt’s direction."
Mr. Shaulis joins BeiGene from Hansa Biopharma, where he served as Chief Commercial Officer and U.S. President. Prior to that, he served as President of Pfizer Inflammation and Immunology for International Developed Markets and previously was Pfizer’s President of North America Oncology.
He joined Pfizer from Teva Pharmaceuticals, where he was Vice President and Global Therapeutic Area Lead, Multiple Sclerosis, with prior experience in senior sales, marketing, strategic customer group, and global roles with Cephalon, Johnson & Johnson and Schering-Plough.
Mr. Shaulis earned his bachelor’s degree from Penn State University and his MBA from the Fuqua School of Business at Duke University.
About BeiGene
BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter), Facebook and Instagram.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s future growth and success in hematology and solid tumors and BeiGene’s plans, commitments, aspirations and goals under the caption "About BeiGene". Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled "Risk Factors" in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.
